**1. Financial Highlights:** Q1 FY26 financial results show revenue decreased 9.7% YoY to ₹145.07 Cr.

EBITDA saw a 17.3% YoY drop to ₹51.70 Cr, with margins contracting to 35.6%. Profit for the period fell 21.9% YoY to ₹34.79 Cr, and PAT margins compressed to 24.0%. **2. Strategic Initiatives & Growth Drivers:** The company commissioned its state-of-the-art Module E production block, significantly boosting reactor capacity to 932 KLPD, enabling enhanced backward integration and new product rollouts.

Two new R&D labs have been established at Lote and Ambernath, focusing on lifecycle management and new product development.

Plans include expanding the controlled drugs portfolio and entering anti-diabetic and anesthetic segments, with a new FDF facility at Ambernath slated for commissioning in H2 FY26. **3. Business Developments:** A significant 10-year exclusive API supplier CMO contract has been secured with a European company, projected to generate peak annual revenue of ₹60 Cr from FY27. The company has also identified two more similar opportunities and recently strengthened its Anesthetic therapy portfolio with a new product launch. **4. Market Position & Competitive Advantage:** A global leader in Anti-histamines, Anti-Allergic, Vitamins, Anti-Asthmatics & Anesthetics with 40+ APIs.

The company benefits from a high export revenue (85%) across 120+ countries and substantial backward integration (81% of Q1 revenue). **5. Investor Implications:** Despite Q1 financial headwinds, strategic investments in R&D and manufacturing capacity, coupled with the new long-term CMO contract, point to a positive growth potential.

The diversified business model and backward integration enhance operational resilience.